Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

被引：16

作者：

Buckstein, Rena ^{[1
]}

Kuruvilla, John ^{[7
]}

Chua, Neil ^{[2
]}

Lee, Christina ^{[1
]}

Macdonald, David A. ^{[3
]}

Al-Tourah, Abdulwahab J. ^{[4
]}

Foo, Alison H. ^{[5
]}

Walsh, Wendy ^{[5
]}

Ivy, S. Percy ^{[6
]}

Crump, Michael

Eisenhauer, Elizabeth A. ^{[5
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada

[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[3] QEII Hlth Sci Ctr, Halifax, NS, Canada

[4] Fraser Valley Ctr, BC Canc Ctr, Surrey, BC, Canada

[5] NCIC Clin Trials Grp, Kingston, ON, Canada

[6] NCI, Rockville, MD USA

[7] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Med Oncol & Hematol, Toronto, ON, Canada

来源：

LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 05期

关键词：

NON-HODGKINS-LYMPHOMA; CIRCULATING ENDOTHELIAL-CELLS; METRONOMIC CHEMOTHERAPY; PROGENITOR CELLS; CANCER-PATIENTS; PROGNOSTIC-SIGNIFICANCE; MICROVESSEL DENSITY; INTERFERON-ALPHA; ELDERLY-PATIENTS; GROWTH-FACTORS;

D O I：

10.3109/10428194.2011.555892

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory DLBCL. Of 19 enrolled patients, 17 eligible patients were evaluable for toxicity and 15 for response. No objective responses were seen and nine patients achieved stable disease (median duration 3.4 months). As a result, the study was closed at the end of the first stage. Grades 3--4 neutropenia and thrombocytopenia were observed in 29%% and 35%%, respectively. There was no relationship between change in circulating endothelial cell numbers (CECs) and bidimensional tumor burden over time. Despite some activity in solid tumors, sunitinib showed no evidence of response in relapsed/refractory DLBCL and had greater than expected hematologic toxicity.</.

引用

页码：833 / 841

页数：9

共 45 条

[11] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Demetri, George D.
van Oosterom, Allan T.
Garrett, Christopher R.
Blackstein, Martin E.
Shah, Manisha H.
Verweij, Jaap
McArthur, Grant
Judson, Ian R.
Heinrich, Michael C.
Morgan, Jeffrey A.
Desai, Jayesh
D Fletcher, Christopher
George, Suzanne
Bello, Carlo L.
Huang, Xin
Baum, Charles M.
Casali, Paolo G.
[J]. LANCET, 2006, 368 (9544) : 1329 - 1338
[12] Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
Dias, S
Hattori, K
Heissig, B
Zhu, ZP
Wu, Y
Witte, L
Hicklin, DJ
Tateno, M
Bohlen, P
Moore, MAS
Rafii, S
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10857 - 10862
[13] Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
Dias, S
Hattori, K
Zhu, ZP
Heissig, B
Choy, M
Lane, W
Wu, Y
Chadburn, A
Hyjek, E
Gill, M
Hicklin, DJ
Witte, L
Moore, MAS
Rafii, S
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) : 511 - 521
[14] Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
Ebos, John M. L.
Lee, Christina R.
Christensen, James G.
Mutsaers, Anthony J.
Kerbel, Robert S.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (43) : 17069 - 17074
[15] El-Maraghi RH, 2008, J CLIN ONCOL, V26, P1346, DOI 10.1200/JCO.2007.13.5913
[16] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
Feugier, P
Van Hoof, A
Sebban, C
Solal-Celigny, P
Bouabdallah, R
Fermé, C
Christian, B
Lepage, E
Tilly, H
Morschhauser, F
Gaulard, P
Salles, G
Bosly, A
Gisselbrecht, C
Reyes, F
Coiffier, B
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4117 - 4126
[17] Antiangiogenesis: A new approach to the treatment of lymphoma
Ganjoo, Kristen
[J]. LEUKEMIA & LYMPHOMA, 2007, 48 (03) : 454 - 455
[18] Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
George, S.
Blay, J. Y.
Casali, P. G.
Le Cesne, A.
Stephenson, P.
DePrimo, S. E.
Harmon, C. S.
Law, C. N. J.
Morgan, J. A.
Ray-Coquard, I.
Tassell, V.
Cohen, D. P.
Demetri, G. D.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1959 - 1968
[19] Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
Gratzinger, Dita
Zhao, Shuchun
Tibshirani, Robert J.
Hsi, Eric D.
Hans, Christine P.
Pohlman, Brad
Bast, Martin
Avigdor, Abraham
Schiby, Ginette
Nagler, Arnon
Byrne, Gerald E., Jr.
Lossos, Izidore S.
Natkunam, Yasodha
[J]. LABORATORY INVESTIGATION, 2008, 88 (01) : 38 - 47
[20] Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes
Gratzinger, Dita
Zhao, Shuchun
Marinelli, Robert J.
Kapp, Amy V.
Tibshirani, Robert J.
Hammer, Anne S.
Hamilton-Dutoit, Stephen
Natkunam, Yasodha
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (04) : 1362 - 1369

← 1 2 3 4 5 →